Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Late-Breaker Posters on Results From Emricasan Phase 2 NAFLD/NASH and ACLF Clinical Trials Poster on Safety and Activity Results From Emricasan Phase 1 Organ Impairment Clinical Trials SAN...
-
SAN DIEGO, April 8, 2015 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver...
-
- Emricasan Safety and Activity Observations and Conclusions from Hepatic Impairment Clinical Trial - - Late-breakers on Detailed Results from NAFLD/NASH and ACLF Clinical Trials - SAN DIEGO,...
-
SAN DIEGO, April 7, 2015 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) announced today its scheduled presentation of the company's programs and outlook at the 14th Annual Needham...
-
SAN DIEGO, April 2, 2015 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver...
-
SAN DIEGO, April 1, 2015 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver...
-
- Conclusions Support Registration Strategy Including NASH Cirrhosis - - Detailed Data to be Presented in Late-Breaker Poster at EASL Meeting - SAN DIEGO, March 26, 2015 (GLOBE NEWSWIRE) --...
-
SAN DIEGO, March 23, 2015 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) and its research collaborator BioReliance, Sigma-Aldrich Corporation's (Nasdaq:SIAL) biologics and...
-
SAN DIEGO, March 11, 2015 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver...
-
SAN DIEGO, March 4, 2015 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver...